Trial Profile
Immunogenicity and Safety of Tetravalent Dengue Vaccine Given in 1-, 2-, or 3- Dose Schedules (STAGE I) Followed by a Single Booster Injection of the Same Vaccine (STAGE II) 1 or 2 Years After the Last Primary Dose in Healthy Subjects 9 to 50 Years of Age in Colombia and the Philippines
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Apr 2021
Price :
$35
*
At a glance
- Drugs CYD TDV (Primary)
- Indications Dengue
- Focus Pharmacodynamics
- Sponsors Sanofi Pasteur
- 01 Apr 2021 Protocol was amended; the original co-primary objectives of non-inferiority of the one-dose and two-dose groups to the three-dose group were altered to include non-inferiority of the two-dose group to the three-dose group only, to be assessed in individuals who were dengue seropositive at baseline.
- 01 Apr 2021 Results published in The Lancet Infectious Diseases
- 24 Aug 2020 Status changed from active, no longer recruiting to completed.